Copyright Reports & Markets. All rights reserved.

Global and China HR+/HER2- Breast Cancer Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global HR+/HER2- Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 CDK4/6 Inhibitors
    • 1.2.3 PARP Inhibitors
    • 1.2.4 PI3K Inhibitor
    • 1.2.5 Others
  • 1.3 Market by Application
    • 1.3.1 Global HR+/HER2- Breast Cancer Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospitals
    • 1.3.3 Cancer Center
    • 1.3.4 Medical Research and Academic Institutions
    • 1.3.5 Ambulatory Surgical Centers
    • 1.3.6 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global HR+/HER2- Breast Cancer Market Perspective (2015-2026)
  • 2.2 Global HR+/HER2- Breast Cancer Growth Trends by Regions
    • 2.2.1 HR+/HER2- Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 HR+/HER2- Breast Cancer Historic Market Share by Regions (2015-2020)
    • 2.2.3 HR+/HER2- Breast Cancer Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top HR+/HER2- Breast Cancer Players by Market Size
    • 3.1.1 Global Top HR+/HER2- Breast Cancer Players by Revenue (2015-2020)
    • 3.1.2 Global HR+/HER2- Breast Cancer Revenue Market Share by Players (2015-2020)
  • 3.2 Global HR+/HER2- Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by HR+/HER2- Breast Cancer Revenue
  • 3.4 Global HR+/HER2- Breast Cancer Market Concentration Ratio
    • 3.4.1 Global HR+/HER2- Breast Cancer Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by HR+/HER2- Breast Cancer Revenue in 2019
  • 3.5 Key Players HR+/HER2- Breast Cancer Area Served
  • 3.6 Key Players HR+/HER2- Breast Cancer Product Solution and Service
  • 3.7 Date of Enter into HR+/HER2- Breast Cancer Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 HR+/HER2- Breast Cancer Breakdown Data by Type (2015-2026)

  • 4.1 Global HR+/HER2- Breast Cancer Historic Market Size by Type (2015-2020)
  • 4.2 Global HR+/HER2- Breast Cancer Forecasted Market Size by Type (2021-2026)

5 HR+/HER2- Breast Cancer Breakdown Data by Application (2015-2026)

  • 5.1 Global HR+/HER2- Breast Cancer Historic Market Size by Application (2015-2020)
  • 5.2 Global HR+/HER2- Breast Cancer Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America HR+/HER2- Breast Cancer Market Size (2015-2026)
  • 6.2 North America HR+/HER2- Breast Cancer Market Size by Type (2015-2020)
  • 6.3 North America HR+/HER2- Breast Cancer Market Size by Application (2015-2020)
  • 6.4 North America HR+/HER2- Breast Cancer Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe HR+/HER2- Breast Cancer Market Size (2015-2026)
  • 7.2 Europe HR+/HER2- Breast Cancer Market Size by Type (2015-2020)
  • 7.3 Europe HR+/HER2- Breast Cancer Market Size by Application (2015-2020)
  • 7.4 Europe HR+/HER2- Breast Cancer Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China HR+/HER2- Breast Cancer Market Size (2015-2026)
  • 8.2 China HR+/HER2- Breast Cancer Market Size by Type (2015-2020)
  • 8.3 China HR+/HER2- Breast Cancer Market Size by Application (2015-2020)
  • 8.4 China HR+/HER2- Breast Cancer Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan HR+/HER2- Breast Cancer Market Size (2015-2026)
  • 9.2 Japan HR+/HER2- Breast Cancer Market Size by Type (2015-2020)
  • 9.3 Japan HR+/HER2- Breast Cancer Market Size by Application (2015-2020)
  • 9.4 Japan HR+/HER2- Breast Cancer Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia HR+/HER2- Breast Cancer Market Size (2015-2026)
  • 10.2 Southeast Asia HR+/HER2- Breast Cancer Market Size by Type (2015-2020)
  • 10.3 Southeast Asia HR+/HER2- Breast Cancer Market Size by Application (2015-2020)
  • 10.4 Southeast Asia HR+/HER2- Breast Cancer Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11Key Players Profiles

  • 11.1 Jiangsu HengRui Medicine
    • 11.1.1 Jiangsu HengRui Medicine Company Details
    • 11.1.2 Jiangsu HengRui Medicine Business Overview
    • 11.1.3 Jiangsu HengRui Medicine HR+/HER2- Breast Cancer Introduction
    • 11.1.4 Jiangsu HengRui Medicine Revenue in HR+/HER2- Breast Cancer Business (2015-2020))
    • 11.1.5 Jiangsu HengRui Medicine Recent Development
  • 11.2 Odonate Therapeutics
    • 11.2.1 Odonate Therapeutics Company Details
    • 11.2.2 Odonate Therapeutics Business Overview
    • 11.2.3 Odonate Therapeutics HR+/HER2- Breast Cancer Introduction
    • 11.2.4 Odonate Therapeutics Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
    • 11.2.5 Odonate Therapeutics Recent Development
  • 11.3 Radius Pharmaceuticals
    • 11.3.1 Radius Pharmaceuticals Company Details
    • 11.3.2 Radius Pharmaceuticals Business Overview
    • 11.3.3 Radius Pharmaceuticals HR+/HER2- Breast Cancer Introduction
    • 11.3.4 Radius Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
    • 11.3.5 Radius Pharmaceuticals Recent Development
  • 11.4 Immunomedics
    • 11.4.1 Immunomedics Company Details
    • 11.4.2 Immunomedics Business Overview
    • 11.4.3 Immunomedics HR+/HER2- Breast Cancer Introduction
    • 11.4.4 Immunomedics Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
    • 11.4.5 Immunomedics Recent Development
  • 11.5 Roche Group
    • 11.5.1 Roche Group Company Details
    • 11.5.2 Roche Group Business Overview
    • 11.5.3 Roche Group HR+/HER2- Breast Cancer Introduction
    • 11.5.4 Roche Group Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
    • 11.5.5 Roche Group Recent Development
  • 11.6 Syndax Pharmaceuticals
    • 11.6.1 Syndax Pharmaceuticals Company Details
    • 11.6.2 Syndax Pharmaceuticals Business Overview
    • 11.6.3 Syndax Pharmaceuticals HR+/HER2- Breast Cancer Introduction
    • 11.6.4 Syndax Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
    • 11.6.5 Syndax Pharmaceuticals Recent Development
  • 11.7 Merck
    • 11.7.1 Merck Company Details
    • 11.7.2 Merck Business Overview
    • 11.7.3 Merck HR+/HER2- Breast Cancer Introduction
    • 11.7.4 Merck Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
    • 11.7.5 Merck Recent Development
  • 11.8 Eagle Pharmaceuticals
    • 11.8.1 Eagle Pharmaceuticals Company Details
    • 11.8.2 Eagle Pharmaceuticals Business Overview
    • 11.8.3 Eagle Pharmaceuticals HR+/HER2- Breast Cancer Introduction
    • 11.8.4 Eagle Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
    • 11.8.5 Eagle Pharmaceuticals Recent Development
  • 11.9 Merrimack Pharmaceuticals
    • 11.9.1 Merrimack Pharmaceuticals Company Details
    • 11.9.2 Merrimack Pharmaceuticals Business Overview
    • 11.9.3 Merrimack Pharmaceuticals HR+/HER2- Breast Cancer Introduction
    • 11.9.4 Merrimack Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
    • 11.9.5 Merrimack Pharmaceuticals Recent Development
  • 11.10 GlaxoSmithKline
    • 11.10.1 GlaxoSmithKline Company Details
    • 11.10.2 GlaxoSmithKline Business Overview
    • 11.10.3 GlaxoSmithKline HR+/HER2- Breast Cancer Introduction
    • 11.10.4 GlaxoSmithKline Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
    • 11.10.5 GlaxoSmithKline Recent Development
  • 11.11 Millennium Pharmaceuticals
    • 10.11.1 Millennium Pharmaceuticals Company Details
    • 10.11.2 Millennium Pharmaceuticals Business Overview
    • 10.11.3 Millennium Pharmaceuticals HR+/HER2- Breast Cancer Introduction
    • 10.11.4 Millennium Pharmaceuticals Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
    • 10.11.5 Millennium Pharmaceuticals Recent Development
  • 11.12 Bayer
    • 10.12.1 Bayer Company Details
    • 10.12.2 Bayer Business Overview
    • 10.12.3 Bayer HR+/HER2- Breast Cancer Introduction
    • 10.12.4 Bayer Revenue in HR+/HER2- Breast Cancer Business (2015-2020)
    • 10.12.5 Bayer Recent Development

12Analyst's Viewpoints/Conclusions

    13Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global HR+/HER2- Breast Cancer Scope and Market Size
    HR+/HER2- Breast Cancer market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global HR+/HER2- Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    CDK4/6 Inhibitors
    PARP Inhibitors
    PI3K Inhibitor
    Others

    Market segment by Application, split into
    Hospitals
    Cancer Center
    Medical Research and Academic Institutions
    Ambulatory Surgical Centers
    Others

    Based on regional and country-level analysis, the HR+/HER2- Breast Cancer market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global HR+/HER2- Breast Cancer market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Jiangsu HengRui Medicine
    Odonate Therapeutics
    Radius Pharmaceuticals
    Immunomedics
    Roche Group
    Syndax Pharmaceuticals
    Merck
    Eagle Pharmaceuticals
    Merrimack Pharmaceuticals
    GlaxoSmithKline
    Millennium Pharmaceuticals
    Bayer

    Buy now